REVIEW

Non-ST elevation acute coronary syndrome in women and the elderly: recent updates and stones still left unturned [version 1; peer review: 2 approved]

Tina Varghese ¹, Nanette K. Wenger ^{1,2}

¹Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

²Emory Heart and Vascular Center, Emory Women's Heart Center, Atlanta, GA, USA

V1 First published: 29 Nov 2018, 7(F1000 Faculty Rev):1865
<https://doi.org/10.12688/f1000research.16492.1>

Latest published: 29 Nov 2018, 7(F1000 Faculty Rev):1865
<https://doi.org/10.12688/f1000research.16492.1>

Abstract

Despite the growing awareness of adverse events with acute coronary syndrome and vigilance to refine pharmacological and interventional therapies, the understanding of how these events present in and affect women and the elderly remains limited. Pathophysiological differences in these subgroups and under-representation in large trials create a medical gap in sex- and age-related outcomes and in our knowledge of how best to detect, diagnose, and treat acute coronary syndrome. This review provides a general overview of recent advances in non-ST elevation myocardial infarction management in women and the elderly and elucidates areas where further exploration is needed.

Keywords

non-ST elevation myocardial infarction, acute coronary syndrome, women, elderly

Open Peer Review

Approval Status

	1	2
version 1		
29 Nov 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Jur Ten Berg**, St. Antonius Hospital, Nieuwegein, The Netherlands
2. **Hani Jneid**, The Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, USA
Carl Zehner, The Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Tina Varghese (tina.varghese@emory.edu)

Author roles: Varghese T: Writing – Original Draft Preparation, Writing – Review & Editing; Wenger NK: Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Varghese T and Wenger NK. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Varghese T and Wenger NK. **Non-ST elevation acute coronary syndrome in women and the elderly: recent updates and stones still left unturned [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):1865 <https://doi.org/10.12688/f1000research.16492.1>

First published: 29 Nov 2018, 7(F1000 Faculty Rev):1865 <https://doi.org/10.12688/f1000research.16492.1>

Introduction

Each year in the US, over 780,000 people experience an acute coronary syndrome (ACS), which in 70% of these patients is non-ST elevation myocardial infarction (NSTEMI)¹. In recent decades, our understanding of the pathophysiology, diagnosis, and management of NSTEMI has significantly expanded. However, data for certain subsets of patients—namely women, who represent half of the worldwide population, and the elderly, a group expected to grow from approximately 524 million in 2010 to 1.5 billion in 2050—are less well elucidated². Both women and the elderly (defined as either older than 65 or older than 75) with NSTEMI are less likely than their male counterparts and younger patients to receive guideline-determined medical therapy (GDMT) and intervention^{3,4}. One evident contributor to this disparity is the predominance of middle-aged men in randomized controlled trials (RCTs) of cardiovascular disease (CVD), and women and the elderly are significantly under-represented. Women represent 43% and individuals older than 75 represent 37% of myocardial infarction (MI) patients in the US. However, women and the elderly are enrolled in RCTs at rates of 25% and 9%, respectively⁵; therefore, risk–benefit ratios for available therapies rely heavily on data extrapolation. Currently, the 5-year risk of death from NSTEMI for women is 42% (versus 29% in men) and 1-year mortality risk after NSTEMI is 20% for patients at least 75 years old and 25% in those older than 85^{6,7}. In contrast, the 30-day and 31- to 365-day mortality risk after any MI (STEMI and NSTEMI) for patients under 50 years of age is about 3.2% and 1.6%, respectively, suggesting a 1-year mortality risk of less than 5% in this younger population⁸.

Increased efforts to intensify inclusivity of these populations in RCTs and apply GDMT for all patients without contraindications are likely responsible for the recently improved 30-day and 1-year mortality outcomes in women and the elderly with NSTEMI^{9–11}. This review examines contemporary updates in the management of women and elderly patients with NSTEMI and highlights areas of uncertainty that require further exploration.

Pathophysiology

The typical pathophysiology underlying ACS is the subtotal, thrombotic occlusion of an epicardial coronary artery with resulting myocardial oxygen supply-and-demand mismatch. Plaque rupture causes half of coronary thrombosis events, and plaque erosion and vasoconstriction at the location of the culprit plaque are responsible for MIs with intact fibrous caps¹².

Elderly

Special considerations in the elderly which predispose this group to a higher incidence and more ominous prognosis of atherothrombotic disease are the presence of increased comorbidities, greater complexity of coronary artery lesions, and the direct effects of aging on the heart. Such detrimental age-related effects include reduced vessel elasticity, attenuated atheroprotective effects of high-density lipoproteins, impaired regenerative ability of cells, endothelial dysfunction, increased tendency for coagulation, and pro-inflammatory state¹³. For instance, elevated C-reactive protein and interleukin-6 levels are reported in the elderly and result in an amplified immune response from

substantial release of pro-inflammatory cytokines; this phenomenon alters normal fibrinolysis pathways, contributing to both the high occurrence of MI in this population and a worse prognosis afterwards. Additionally, the age-related deterioration in organ capacities can negatively impact pharmacodynamics and pharmacokinetics, which may result in undesired medication interactions and side effects¹³.

Women

In addition to traditional CVD risk factors, there are additional pathophysiological processes experienced by women that require elucidation for appropriate diagnostic and therapeutic protocols to be established. Such areas of ambiguity include the effects of reproductive hormones on inflammatory markers, fat distribution, and atherosclerotic burden as well as a clearer understanding of mental stress-induced and vascular dysfunction-induced ischemia, which is believed to occur more commonly in women than in men and demonstrates the complexity of ACS beyond simply culprit lesion diagnosis^{14–16}. Microvascular dysfunction—theorized to develop from a sex-specific remodeling response to arterial injury or atherosclerosis—accounts for why women have less anatomical coronary artery disease (CAD) but paradoxically more angina and ischemia than do men¹⁷.

In the PESA (Progression of Early Subclinical Atherosclerosis) study of asymptomatic middle-aged patients, the prevalences of subclinical atherosclerotic heart disease in men versus women were 15% and 3% (40 to 44 years of age; $p < 0.001$), 24% and 5% (45 to 49 years of age; $p < 0.001$), and 43% and 10% (50 to 54 years of age; $p < 0.001$), respectively¹⁸. Although multiple factors contribute to the presence of CAD, estrogen is believed to play a protective and pleiotropic role against CAD development in premenopausal women and may partially explain the aforementioned and widening disparity in heart disease prevalence with age between the sexes. Estrogen reduces platelet reactivity and thus helps inhibit platelet aggregation in premenopausal women because of the presence of estrogen receptors on platelet surfaces¹⁹. Estrogen also improves traditional CVD risk factors, improving lipid levels and reducing the incidence of type 2 diabetes²⁰. Aside from microvascular and hormonal influences, non-traditional risk factors account for sex differences in CAD, including psychosocial risk factors (for example, low socioeconomic status, anxiety and depression, and social isolation), systemic autoimmune disease, and complications of pregnancy (for example, hypertension- and diabetes-related and preterm delivery)^{17,21,22}.

Whereas plaque *rupture* is the major pathophysiological cause (76%) of thrombotic, fatal coronary artery occlusions in men, it accounts for only 55% of fatal MIs in women²³. Higher occurrences of plaque *erosion* are noted in women, especially younger women^{14,24}. Plaque erosion and the less-common non-atherosclerotic mechanisms for MI, such as coronary artery spasm and spontaneous coronary artery dissection, help explain the more frequent finding of ACS without angiographically obstructive disease in women compared with men^{25,26}. The 2018 publication of the Fourth Universal Definition of MI clarifies the existence of MINOCA (myocardial infarction with non-obstructive coronary

arteries), which implies the presence of ischemia-induced myocyte injury without obstructive CAD (at least 50% diameter stenosis in a major epicardial artery) as its etiology. MINOCA is more commonly seen in women than in men and in NSTEMI than in STEMI²⁶. This broadened nomenclature for MI classification creates opportunities to improve methods for differentiating plaque characteristics, discovering more specific management approaches for each underlying mechanism of ACS, and improving outcomes.

Presentation

Although both women and elderly patients usually present with typical symptoms of MI, atypical presentations (for example, back pain, nausea, dyspnea, acute fatigue, and lack of pain) are more common in these subgroups than in men²⁷.

Elderly

With increasing age, the number of patients with ACS who present with Killip class III or IV congestive heart failure symptoms rises²⁸. Also notable in the elderly is the occurrence of abnormal baseline electrocardiograms, which can obscure the findings of ischemia. Such variability in clinical and electrocardiographic presentation in the elderly can cause ACS misdiagnosis and requires a higher level of suspicion of a coronary event. Moreover, frailty, polypharmacy, and features unique to the elderly (Figure 1) make risk stratification, treatment, and outcomes a further challenge but are vital for appropriately tailored management.

Women

The VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI [Acute MI] Patients) study, in which nearly 3,000 people were interviewed during their index MI hospitalization, demonstrated that women are more likely to present with non-chest pain symptoms and are more likely to ascribe their MI symptoms to anxiety or stress²⁹. Younger women (younger than 45) with MI were much more likely than age-matched men to present without chest pain; the lack of chest pain is associated with higher mortality rates, although this correlation disappears with age³⁰. The higher death rates in young women possibly result from delayed diagnosis and perhaps also from

differing pathophysiology (for example, younger women experience more plaque erosion than rupture) that may not be appropriately addressed with current interventional strategies.

Pharmacology

The medical management of ACS uses anti-ischemic medications (for example, beta-blockers and nitrates), secondary prevention medications (for example, statins), medications to help improve systolic dysfunction if present (for example, beta-blockers and angiotensin-converting enzyme [ACE] inhibitors), and antithrombotic therapy¹. Special attention should be paid to polypharmacy, age-related change in pharmacokinetics, and drug–drug interactions in the older population and teratogenic consequences in pregnant or childbearing-aged women.

Elderly

Advanced age is associated with excess dosing of antithrombotic medications in NSTEMI³¹. Weight and renal clearance/glomerular filtration rate should be considered when dosing antiplatelet and anticoagulant therapies¹. Hemorrhagic complications of ACS management are particularly feared in the elderly because of the increased susceptibility to bleeding and risk of significant sequelae from such events. For patients requiring both dual antiplatelet therapy (DAPT) for NSTEMI and anticoagulation with either warfarin or a direct oral anticoagulant (DOAC) for other conditions (that is, atrial fibrillation, prosthetic valves, or left ventricular thrombus), the American College of Cardiology/American Heart Association (ACC/AHA) does not have specific recommendations for which P2Y12 inhibitor should be used in this scenario. However, newer antiplatelet agents (for example, ticagrelor) may want to be avoided in patients requiring triple therapy owing to their increased bleeding risk without easy reversibility¹. One of the newer agents, prasugrel, should be avoided in general in those patients who are older than 75, weigh less than 60 kg, or have a history of stroke owing to excessive bleeding risk without clear benefit¹.

The 2016 ACC/AHA focused update suggests that in patients with high risk of bleeding (for example, taking an oral anti-coagulant medication) or high risk of bleeding complication, discontinuation of P2Y12 medication at 6 months after NSTEMI treated with drug-eluting stent(s) could be considered (class of recommendation IIb and level of evidence C-LD)³². Other considerations to reduce bleeding include the addition of proton pump inhibitors for those at risk of gastrointestinal bleeding while on DAPT, narrowing the international normalized ratio goal to 2.0 to 2.5 if on warfarin, and switching triple therapy to dual earlier on (that is, triple therapy for 1 month post-percutaneous coronary intervention, or post-PCI, followed by DOAC with only clopidogrel or aspirin for 11 months)^{32,33}. During an NSTEMI, reduced bleeding risk may be achieved by using bivalirudin, a direct thrombin inhibitor, in the elderly instead of glycoprotein IIb/IIIa inhibitor with unfractionated heparin¹. Additionally, pooled analysis from three large RCTs of cangrelor, an intravenous platelet inhibitor, administered at the time of PCI showed reduction of the primary composite outcome of death, MI, ischemia-driven revascularization, and stent thrombosis by 19% at 48 hours when compared with clopidogrel, and the benefit was more marked

Figure 1. Unique factors to consider in risk stratification of elderly patients presenting with acute coronary syndrome. BMI, body mass index; CKD, chronic kidney disease

among patients 75 years old or older. An increase in severe bleeding was not observed³⁴. Therefore, this drug represents a potential alternative for patients who require platelet inhibition but cannot tolerate oral agents. Additional studies in the elderly are required before significant further conclusions can be made on benefits versus risks.

Women

The 2014 ACC/AHA NSTEMI guidelines recommend that NSTEMI in women be treated with the same medications as those used in men¹. The one clear exception to routine ACS pharmacological agents in women is in pregnancy; ACE inhibitors, angiotensin receptor blockers, and statins should be avoided because of their teratogenic effects^{35,36}. After an AMI, menopausal hormone therapy should not be initiated or should be discontinued (if taking already) unless benefits strongly outweigh risks; data from the Women's Health Initiative RCT and from the Heart and Estrogen/Progestin Replacement Study (HERS) raise concern for increased CV events with estrogen or estrogen-progesterone pills^{37,38}.

As with the elderly, women with NSTEMI receive excess antithrombotic medication dosing than appropriate for their weight or renal function (or both), and this is partly responsible for the higher risk of in-hospital bleeds and access-related complications after PCI in women³¹. Women also experience frequent fluctuations in prothrombotic tendency throughout their lives because of menstrual cycles, use of oral contraceptives, pregnancy, menopause, and hormone replacement therapy, requiring careful consideration when using and dosing blood thinners in AMI, including during the prothrombotic state of pregnancy¹⁹. Women are less likely than men to be adherent to antiplatelet therapy, and this is possibly because of the higher bleeding rates³⁹. They are likely to experience both underutilization and early discontinuation of other medications categorized as GDMT despite equal efficacy of medications^{40,41}. In the MINOCA population, patients are less likely to receive beta-blockers, ACE inhibitors, and statins compared with patients with obstructive CAD on 3-month post-angiography follow-up, even though increased mortality and MI rates are associated with this diagnosis; this discrepancy calls for increased evaluation of MINOCA outcomes and awareness of its prognosis despite a more benign anatomical appearance^{42,43}. Evaluation of new pharmacotherapies should be pursued for improved management of microvascular dysfunction; some evidence suggests benefit from spironolactone, tricyclic antidepressants, and ranolazine^{44–46}.

Revascularization

All patients presenting with NSTEMI should receive appropriate pharmacological therapies and undergo evaluation for invasive intervention, which currently consists of two pathways. An invasive strategy refers to coronary angiography, subdivided into early invasive (angiography within 24 hours of NSTEMI presentation) and delayed invasive (within 25 to 72 hours) strategies. An ischemia-guided, previously termed “conservative”, strategy implies coronary angiography for those who (a) have refractory angina despite GDMT as tolerated, (b) demonstrate objective ischemic signs on non-invasive stress imaging,

and/or (c) have poor prognostic features: that is, high GRACE (Global Registry of Acute Coronary Events) (Table 1) or TIMI (Thrombolysis in Myocardial Infarction) risk scores^{1,47,48}. A meta-analysis of the FRISC-II, ICTUS, and RITA-3 RCTs showed fewer CV deaths and non-fatal MIs at 5 years with a routine invasive strategy⁴⁹. Current guidelines recommend immediate coronary angiography in patients with NSTEMI with concomitant refractory angina or electrical/hemodynamic instability and an early invasive strategy for those with high-risk but stable NSTEMI (for example, GRACE risk score of more than 140, change in troponins, or new ST depression on electrocardiogram)¹.

The recently published VERDICT (Very Early vs. Deferred Invasive evaluation using Computerized Tomography) RCT showed that a very early invasive strategy (<12 hours of diagnosis) did not significantly improve long-term outcomes (median follow-up of 4.3 years) in patients with NSTEMI compared with an invasive strategy performed within 48 to 72 hours of diagnosis, although benefit was noted in a high-risk subgroup of patients with a GRACE risk score of more than 140⁵⁰. No benefit was noted in women or patients over the age of 64, but the majority of the studied population were middle-aged men⁵⁰. Inclusion of women and older patients is needed to definitively assess very early invasive outcomes in these two populations.

Elderly

Short- and long-term outcome data suggest that an early invasive strategy confers a significant absolute and relative risk reduction in patients 65 years of age or older, yet this population is less likely to receive such treatment because risk factors that put elderly patients at higher risk for morbidity and mortality in ACS may paradoxically be viewed as relative contraindications to invasive management^{6,51–53}. However, in patients 75 years old or older, the majority of deaths within 1 year of an NSTEMI originate from cardiac ischemia, and the benefit from revascularization appears to progressively rise with background risk, bolstering the need for better and earlier treatment options^{54,55}.

A recent meta-analysis demonstrated reduced 30-day and 12-month mortality rates in the invasive compared with the conservative

Table 1. Global Registry of Acute Coronary Events (GRACE) risk score risk factors.

Age in years
Heart rate in beats per minute
Systolic blood pressure in millimeters of mercury
Creatinine in micromoles per liter
Congestive heart failure Killip class
Cardiac arrest at admission
ST segment deviation on electrocardiogram
Elevated cardiac enzymes/markers

Risk assessment tool to predict 6-month risk of mortality or myocardial infarction after initial presentation with acute coronary syndrome.

group among an elderly population, but these results were driven primarily by observational studies—which are subject to selection bias—and were no longer evident when only RCTs were analyzed; analysis of the RCTs suggested reduced 1-year re-infarction and possibly reduced stroke rates with the invasive strategy⁵⁶. Unlike with medical management, the subject of revascularization in older adults contains several recent RCTs dedicated exclusively to this population. The Italian Study, published in 2012, was the first RCT to evaluate revascularization strategies in 313 NSTEMI patients who were 75 or older⁵⁷. A strong benefit to early revascularization was not observed, and this is likely because the study was underpowered, but it demonstrated a statistically significant reduction in clinical events in patients with elevated troponin levels on admission. Four years later, the After Eighty Study delivered more convincing evidence supporting guideline-recommended routine invasive management of NSTEMI or unstable angina over conservative management in patients aged 80 or older⁵⁸. The invasive strategy outperformed conservative measures in the composite primary outcome, and the benefit was driven primarily by reductions in MI and urgent revascularizations. Whether the benefit of this strategy existed in patients older than 90 was unclear. Applicability to the elderly population as a whole is perhaps too optimistic, as many older patients were excluded from the study. However, the patients included represent a higher-risk elderly population given the presence of increased comorbidities compared with prior studies, yet fewer contrast-induced nephropathy or major bleeding incidences were noted in the invasive group than in previous trials⁵⁸. The lower risk of bleeding may be a result of both increased radial artery access (which has been associated with fewer access site complications and bleeding than femoral access) and careful selection of stable patients, further supporting the need for appropriate screening of patients^{58,59}.

Trials such as the Italian Study and After Eighty Study confirm that invasive management of NSTEMI can and should be safely performed in stable elderly patients despite their clinical complexity. Although such conclusions align with established guidelines, these RCTs are unique in that they are geared toward this specific population, allowing us to forego dependence solely on subgroup analysis and extrapolation. As with PCI evaluation, coronary artery bypass grafting (CABG) evaluation should not be withheld from elderly patients who present with NSTEMI, especially those with diabetes or systolic dysfunction (or both), should their coronary angiography reveal left main or multivessel CAD¹.

Women

A meta-analysis of RCTs involving invasive versus conservative revascularization in patients with NSTEMI between 1970 and 2008 illustrated a 33% reduced odds of MI, death, or re-hospitalization for ACS when using an early invasive strategy in women with high-risk features, such as elevated troponin levels⁶⁰. An early invasive strategy offered no substantial benefit, and perhaps may cause increased MI or death, in women without biomarker elevation; this is reflected in other studies (for example, TACTICS-TIMI 18) and in current guidelines^{1,60}. Consistent with European Society of Cardiology guidelines, revascularization in pregnant women has a class IIa recommendation and can

be considered if medical therapy is unsuccessful at addressing life-threatening complications^{1,61}.

Despite the guidelines, women are less likely than men to undergo revascularization with NSTEMI. In a study involving 23,863 patients with ACS, women were less likely than men to receive coronary angiography, revascularization, or CABG both before and after adjustment for confounders⁶². Causes include inherent gender bias and underestimation of patient risk, atypical symptoms on presentation, conflicting data from post-hoc analysis of trials regarding revascularization benefit, and 1.5- to 4-fold-higher vascular complications from the procedure^{29,62–66}. Rahimtoola *et al.* reported a higher unadjusted operative mortality risk and lower long-term survival for women undergoing CABG compared with men, but sex was not an independent risk factor for lower survival⁶⁷. The BARI (Bypass Angioplasty Revascularization Investigation) trial showed that women did as well as men, if not better, at 5-year follow-up post-CABG and had similar in-hospital mortality rates⁶⁸. These findings emphasize that careful assessment of risk–benefit ratios must be performed before women undergo PCI or surgical revascularization, but given the clearly established benefit of revascularization in AMI, our medical community must adhere to consistent application of evidence-based approaches and guideline-directed revascularization when appropriate.

Cardiac rehabilitation

Comprehensive cardiac rehabilitation (CR) is a class 1 recommendation in the continuum of care in patients with AMI, lessening cardiovascular mortality by 26%, reducing hospital admissions by 18%, and improving quality of life^{1,69–71}.

Elderly

Elderly patients tend to be less fit than younger patients at baseline; thus, ACS can accelerate deconditioning. Complications of MIs and of revascularization procedures, compounded with prolonged hospitalizations, lead to further deconditioning⁶⁹. Therefore, elderly patients stand to gain significant physical and emotional benefit with supervised exercise programs, but they are frequently under-prescribed CR⁷². Studies have illustrated short-, moderate-, and long-term (3 months, 1 year, and 5 years, respectively) improvement in outcomes in the elderly with CR, and therefore increased awareness of CR availability and a willingness to refer patients should be present^{73,74}.

Women

Women are also less likely to be referred to or use CR after an AMI⁷². Data from the Centers for Disease Control and Prevention show that, among MI survivors, CR is used in only 36.4% of men and in an even lower percentage of women (28.8%)⁷⁵. A recent study examining the high dropout rate of women found five general explanations: intrapersonal reasons (for example, health beliefs), interpersonal reasons (for example, obligations for work and caregiver of family), logistical reasons (for example, transportation), CR program characteristics (for example, related to CR equipment or timing), and health-system reasons (for example, long waiting list)⁷⁶. Other barriers to referral or completion of CR (or both) by women include non-modifiable factors (for example, age and diagnosis) and less easily

modifiable factors (for example, socioeconomic status/depression and lower education level)⁷⁷. Methods to improve CR participation must be further assessed and implemented; interventions include more flexible times, incentive programs, and alternative (that is, home-based or smartphone-based) CR models to lessen the burden of barriers to CR completion for all patients with CAD, as this issue extends beyond sex and age⁷⁷.

Conclusions

A combination of lack of research outcomes, delay in recognition of ACS symptoms, and less-aggressive interventions because of fear of adverse effects results in a large discrepancy between guideline-emphasized care and the care that is actually provided to women and the elderly. Fortunately, in the past several decades, investigators have begun exploring the distinctive components of heart disease in these two populations to move away from a one-size-fits-all treatment paradigm. “Sex-specific differences” and “geriatric cardiology” are no longer foreign terms but rather arenas of new exploration and spectacular results, but the road to receiving care equal to the care provided to middle-aged men with CAD is challenging. Earlier detection of NSTEMI in these subgroups, awareness of differing pathophysiological mechanisms, increased enrollment in RCTs, evaluation of age- and sex-specific influences on study results, and promotion of secondary prevention by addressing barriers to care are paramount to helping women and the elderly receive guideline-based management in the setting of severe cardiac

events. The multiple layers underlying the pathobiological mechanisms behind age- and sex-based differences in CAD epidemiology must be peeled away via basic science and clinical research for improved health outcomes and reduced mortality rates. Only an extensive understanding and appreciation of this intricate medical landscape will allow an all-inclusive ACS treatment approach.

Abbreviations

ACC/AHA, American College of Cardiology/American Heart Association; ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CR, cardiac rehabilitation; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; GDMT, guideline-directed medical therapy; GRACE, Global Registry of Acute Coronary Events; MINOCA, myocardial infarction with non-obstructive coronary arteries; NSTEMI, non-ST segment elevation myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; STEMI, ST segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Amsterdam EA, Wenger NK, Brindis RG, *et al.*: **2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Circulation*. 2014; 130(25): e344–426. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
2. World Health Organization: **Global health and aging.** (National Institutes of Aging; National Institutes of Health). 2011. [Reference Source](#)
3. Alexander KP, Roe MT, Chen AY, *et al.*: **Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative.** *J Am Coll Cardiol*. 2005; 46(8): 1479–87. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Bugiardini R, Yan AT, Yan RT, *et al.*: **Factors influencing underutilization of evidence-based therapies in women.** *Eur Heart J*. 2011; 32(11): 1337–44. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Lee PY, Alexander KP, Hammill BG, *et al.*: **Representation of elderly persons and women in published randomized trials of acute coronary syndromes.** *JAMA*. 2001; 286(6): 708–13. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Alexander KP, Newby LK, Cannon CP, *et al.*: **Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.** *Circulation*. 2007; 115(19): 2549–69. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Kvakestad KM, Wang Fagerland M, Eritsland J, *et al.*: **Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study.** *BMC Cardiovasc Disord*. 2017; 17(1): 75. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
8. Schmidt M, Szépligeti S, Horváth-Puhó E, *et al.*: **Long-Term Survival Among Patients With Myocardial Infarction Before Age 50 Compared With the General Population: A Danish Nationwide Cohort Study.** *Circ Cardiovasc Qual Outcomes*. 2016; 9(5): 523–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
9. Schiele F, Meneveau N, Seronde MF, *et al.*: **Changes in management of elderly patients with myocardial infarction.** *Eur Heart J*. 2009; 30(8): 987–94. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
10. De Carlo M, Morici N, Savonitto S, *et al.*: **Sex-Related Outcomes in Elderly Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the Italian Elderly ACS Study.** *JACC Cardiovasc Interv*. 2015; 8(6): 791–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
11. Puymirat E, Aissaoui N, Cayla G, *et al.*: **Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management.** *Am J Med*. 2017; 130(5): 555–63. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
12. Niccoli G, Montone RA, Di Vito L, *et al.*: **Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome.** *Eur Heart J*. 2015; 36(22): 1377–84. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Badimon L, Bugiardini R, Cubedo J: **Pathophysiology of acute coronary syndromes in the elderly.** *Int J Cardiol*. 2016; 222: 1105–9. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Bairey Merz CN, Shaw LJ, Reis SE, *et al.*: **Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease.** *J Am Coll Cardiol*. 2006; 47(3 Suppl): S21–9. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Humphries KH, Izadnegahdar M, Sedlak T, *et al.*: **Sex differences in cardiovascular disease - Impact on care and outcomes.** *Front Neuroendocrinol*. 2017; 46: 46–70. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Martin EA, Tan SL, MacBride LR, *et al.*: **Sex differences in vascular and endothelial responses to acute mental stress.** *Clin Auton Res*. 2008; 18(6): 466–73. [PubMed Abstract](#) | [Publisher Full Text](#)

- 339–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Shaw LJ, Bugiardini R, Merz CN: **Women and ischemic heart disease: evolving knowledge.** *J Am Coll Cardiol.* 2009; **54**(17): 1561–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. **F** Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, *et al.*: **Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study.** *Circulation.* 2015; **131**(24): 2104–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 19. Patti G, De Caterina R, Abbate R, *et al.*: **Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper.** *Eur Heart J.* 2014; **35**(33): 2213–23b.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Murphy E: **Estrogen signaling and cardiovascular disease.** *Circ Res.* 2011; **109**(6): 687–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Varghese T, Hayek SS, Shekiladze N, *et al.*: **Psychosocial Risk Factors Related to Ischemic Heart Disease in Women.** *Curr Pharm Des.* 2016; **22**(25): 3853–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Titterton JS, Hung OY, Saraf AP, *et al.*: **Gender differences in acute coronary syndromes: focus on the women with ACS without an obstructing culprit lesion.** *Expert Rev Cardiovasc Ther.* 2018; **16**(4): 297–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. **F** Falk E, Nakano M, Bentzon JF, *et al.*: **Update on acute coronary syndromes: the pathologists' view.** *Eur Heart J.* 2013; **34**(10): 719–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 24. **F** Farb A, Burke AP, Tang AL, *et al.*: **Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.** *Circulation.* 1996; **93**(7): 1354–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 25. Olson MB, Kelsey SF, Matthews K, *et al.*: **Symptoms, myocardial ischaemia and quality of life in women: results from the NHLBI-sponsored WISE Study.** *Eur Heart J.* 2003; **24**(16): 1506–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Thygesen K, Alpert JS, Jaffe AS, *et al.*: **Fourth universal definition of myocardial infarction (2018).** *Eur Heart J.* 2018.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Culic V, Eterović D, Mirić D, *et al.*: **Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors.** *Am Heart J.* 2002; **144**(6): 1012–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Rosengren A, Wallentin L, Simoons M, *et al.*: **Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey.** *Eur Heart J.* 2006; **27**(7): 789–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. **F** Lichtman JH, Lefkowitz EC, Safdar B, *et al.*: **Sex Differences in the Presentation and Perception of Symptoms Among Young Patients With Myocardial Infarction: Evidence from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients).** *Circulation.* 2018; **137**(8): 781–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 30. Canto JG, Rogers WJ, Goldberg RJ, *et al.*: **Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality.** *JAMA.* 2012; **307**(8): 813–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. **F** Alexander KP, Chen AY, Roe MT, *et al.*: **Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.** *JAMA.* 2005; **294**(24): 3108–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 32. **F** Levine GN, Bates ER, Bittl JA, *et al.*: **2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.** *J Am Coll Cardiol.* 2016; **68**(10): 1082–115.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. Humbert X, Roule V, Chequiel M, *et al.*: **Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease.** *Int J Cardiol.* 2016; **222**: 1079–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. **F** Steg PG, Bhatt DL, Hamm CW, *et al.*: **Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.** *Lancet.* 2013; **382**(9909): 1981–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 35. Bullo M, Tschumi S, Bucher BS, *et al.*: **Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.** *Hypertension.* 2012; **60**(2): 444–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Edison RJ, Muenke M: **Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins.** *Am J Med Genet A.* 2004; **131**(3): 287–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Rossouw JE, Anderson GL, Prentice RL, *et al.*: **Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.** *JAMA.* 2002; **288**(3): 321–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Hulley S, Grady D, Bush T, *et al.*: **Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.** *JAMA.* 1998; **280**(7): 605–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Kumbhani DJ, Fonarow GC, Cannon CP, *et al.*: **Predictors of adherence to performance measures in patients with acute myocardial infarction.** *Am J Med.* 2013; **126**(1): 74.e1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Mehta LS, Beckie TM, DeVon HA, *et al.*: **Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association.** *Circulation.* 2016; **133**(9): 916–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Hsue PY, Bittner VA, Betteridge J, *et al.*: **Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.** *Am J Cardiol.* 2015; **115**(4): 447–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Adatia F, Galway S, Grubisic M, *et al.*: **Cardiac Medication Use in Patients with Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease.** *J Womens Health (Larchmt).* 2017; **26**(11): 1185–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. Gulati M, Cooper-DeHoff RM, McClure C, *et al.*: **Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: A report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project.** *Arch Intern Med.* 2009; **169**(9): 843–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. **F** Garg R, Rao AD, Baimas-George M, *et al.*: **Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.** *Diabetes.* 2015; **64**(1): 236–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Cox ID, Hann CM, Kaski JC: **Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms.** *Eur Heart J.* 1998; **19**(2): 250–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Rayner-Hartley E, Sedlak T: **Ranolazine: A Contemporary Review.** *J Am Heart Assoc.* 2016; **5**(3): e003196.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Fox KA, Dabbous OH, Goldberg RJ, *et al.*: **Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE).** *BMJ.* 2006; **333**(7578): 1091.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Antman EM, Cohen M, Bernink PJ, *et al.*: **The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.** *JAMA.* 2000; **284**(7): 835–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Fox KA, Clayton TC, Damman P, *et al.*: **Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data.** *J Am Coll Cardiol.* 2010; **55**(22): 2435–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Kofoed KF, Kelbaek H, Hansen PR, *et al.*: **Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome: the VERDICT (Very Early vs Deferred Invasive evaluation using Computerized Tomography) - Randomized Controlled Trial.** *Circulation.* 2018.
[Reference Source](#)
 51. Damman P, Clayton T, Wallentin L, *et al.*: **Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials.** *Heart.* 2012; **98**(3): 207–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Devlin G, Gore JM, Elliott J, *et al.*: **Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events.** *Eur Heart J.* 2008; **29**(10): 1275–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Sanchis J, Núñez J, Bodí V, *et al.*: **Influence of comorbid conditions on one-year outcomes in non-ST-segment elevation acute coronary syndrome.** *Mayo Clin Proc.* 2011; **86**(4): 291–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Morici N, Savonitto S, Murena E, *et al.*: **Causes of death in patients ≥75 years of age with non-ST-segment elevation acute coronary syndrome.** *Am J Cardiol.* 2013; **112**(1): 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Di Bari M, Balzi D, Fracchia S, *et al.*: **Decreased usage and increased effectiveness of percutaneous coronary intervention in complex older patients with acute coronary syndromes.** *Heart.* 2014; **100**(19): 1537–42.
[PubMed Abstract](#) | [Publisher Full Text](#)

56. **F** Saraswat A, Rahman A, Singh K: **An Invasive vs a Conservative Approach in Elderly Patients with Non-ST-Segment Elevation Myocardial Infarction: Systematic Review and Meta-Analysis.** *Can J Cardiol.* 2018; **34**(3): 274–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
57. **F** Savonitto S, Cavallini C, Petronio AS, *et al.*: **Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial.** *JACC Cardiovasc Interv.* 2012; **5**(9): 906–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. **F** Tegn N, Abdelnoor M, Aaberge L, *et al.*: **Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): An open-label randomised controlled trial.** *Lancet.* 2016; **387**(10023): 1057–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. **F** Cantor WJ, Mehta SR, Yuan F, *et al.*: **Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial.** *Am Heart J.* 2015; **170**(5): 880–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. O'Donoghue M, Boden WE, Braunwald E, *et al.*: **Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.** *JAMA.* 2008; **300**(1): 71–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, *et al.*: **ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).** *Eur Heart J.* 2011; **32**(24): 3147–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. **F** Worrall-Carter L, McEvedy S, Wilson A, *et al.*: **Gender Differences in Presentation, Coronary Intervention, and Outcomes of 28,985 Acute Coronary Syndrome Patients in Victoria, Australia.** *Womens Health Issues.* 2016; **26**(1): 14–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. **F** Capranzano P, Tamburino C, Tamburino C: **Revascularization vs. Optimal Medical Therapy in Women with NSTEMI-ACS.** *Curr Pharm Des.* 2016; **22**(25): 3905–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Poon S, Goodman SG, Yan RT, *et al.*: **Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes.** *Am Heart J.* 2012; **163**(1): 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Lansky AJ, Hochman JS, Ward PA, *et al.*: **Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.** *Circulation.* 2005; **111**(7): 940–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Lansky AJ: **Outcomes of percutaneous and surgical revascularization in women.** *Prog Cardiovasc Dis.* 2004; **46**(4): 305–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Rahimtoola SH, Bennett AJ, Grunkemeier GL, *et al.*: **Survival at 15 to 18 years after coronary bypass surgery for angina in women.** *Circulation.* 1993; **88**(5 Pt 2): II71–8.
[PubMed Abstract](#)
68. Jacobs AK, Kelsey SF, Brooks MM, *et al.*: **Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI).** *Circulation.* 1998; **98**(13): 1279–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Wenger NK: **Current status of cardiac rehabilitation.** *J Am Coll Cardiol.* 2008; **51**(17): 1619–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Heran BS, Chen JM, Ebrahim S, *et al.*: **Exercise-based cardiac rehabilitation for coronary heart disease.** *Cochrane Database Syst Rev.* 2011; (7): CD001800.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. **F** Anderson L, Oldridge N, Thompson DR, *et al.*: **Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis.** *J Am Coll Cardiol.* 2016; **67**(1): 1–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
72. Leon AS, Franklin BA, Costa F, *et al.*: **Cardiac rehabilitation and secondary prevention of coronary heart disease: An American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation.** *Circulation.* 2005; **111**(3): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. **F** Rodrigues P, Santos M, Sousa MJ, *et al.*: **Cardiac Rehabilitation after an Acute Coronary Syndrome: The Impact in Elderly Patients.** *Cardiology.* 2015; **131**(1): 177–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. **F** Hammill BG, Curtis LH, Schulman KA, *et al.*: **Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries.** *Circulation.* 2010; **121**(1): 63–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
75. **F** Fang J, Ayala C, Luncheon C, *et al.*: **Use of Outpatient Cardiac Rehabilitation Among Heart Attack Survivors - 20 States and the District of Columbia, 2013 and Four States, 2015.** *MMWR Morb Mortal Wkly Rep.* 2017; **66**(33): 869–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. **F** Resurrección DM, Moreno-Peral P, Gómez-Herranz M, *et al.*: **Factors associated with non-participation in and dropout from cardiac rehabilitation programmes: a systematic review of prospective cohort studies.** *Eur J Cardiovasc Nurs.* 2018; **14**: 1474515118783157.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
77. **F** Supervía M, Medina-Inojosa JR, Yeung C, *et al.*: **Cardiac Rehabilitation for Women: A Systematic Review of Barriers and Solutions.** *Mayo Clin Proc.* 2017; **92**(4): 565–577. pii: S0025-6196(17)30026-5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Hani Jneid

Division of Cardiology, Baylor College of Medicine, The Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, TX, 77030, USA

Carl Zehner

Division of Cardiology, Baylor College of Medicine, The Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, TX, 77030, USA

Competing Interests: No competing interests were disclosed.

2. Jur Ten Berg

Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research